Frontline Therapies Archives

October 31, 2023

Venetoclax Combined with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Five years after completing venetoclax – obinutuzumab to treat chronic lymphocytic leukemia (CLL), over half of the treatment-naive patients remained in remission, and over 60% did not require second-line treatment, including many high-risk patients.

October 31, 2023

Ibrutinib Combined with Venetoclax for Treatment of CLL: 4 Year Follow-Up

With a four-year follow-up, fixed-duration I + V continues to provide deep, durable remissions with clinically meaningful progression-free survival (PFS) and time off treatment, including in patients with high-risk disease features.

September 15, 2023

ASCO 2023: Dr. Jennifer Woyach on Combination Ibrutinib, Venetoclax, and Obinutuzumab for Previously Untreated CLL

In the setting of the COVID-19 pandemic, progression-free survival with first-line ibrutinib + venetoclax + obinutuzumab treatment was not superior to ibrutinib + obinutuzumab for older patients with previously untreated CLL. Follow-up remains ongoing, and many patients in the ibrutinib + venetoclax + obinutuzumab arm achieved undetectable measurable residual

August 16, 2023

Treatment Outcomes for Patients with CLL and SLL Treated with First Line Ibrutinib Versus Chemoimmunotherapy

More research is presented again, proving that targeted therapies, in this case, ibrutinib, are significantly superior to chemoimmunotherapy (CIT) in front-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL / SLL).

August 16, 2023

A Study of Frontline Therapy in Adults 80 Years and Older with Chronic Lymphocytic Leukemia (CLL)

In those over 80 with chronic lymphocytic leukemia (CLL), older age and not being treated with a novel agent frontline were associated with increased mortality. The leading cause of death in this group was the CLL itself.

May 31, 2023

ASH 2022: Adverse Events from BTK Inhibitors in Clinical Trials

This is the largest meta-analysis of AEs reported with covalent BTKIs. The results help us better understand the side effects of BTKIs in CLL

April 26, 2023

ASH 2022: Dr. Bill Wierda on Ibrutinib Combined with Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia (CLL)

The combination of ibrutinib plus venetoclax is an effective first-line treatment for high-risk chronic lymphocytic leukemia (CLL)

April 26, 2023

ASH 2022: Dr. Neil Kay on Combination Therapies for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

We discuss combination therapies for CLL and SLL, focusing on the combination of ibrutinib plus venetoclax.

April 26, 2023

ASH 2022: Dr. Bill Wierda on Acalabrutinib as a First-line Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Final data from a phase 1/2 clinical trial with six years of follow-up show that first-line acalabrutinib produces high response rates and rapid, durable responses in patients with CLL

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Frontline Therapies

Venetoclax Combined with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Ibrutinib Combined with Venetoclax for Treatment of CLL: 4 Year Follow-Up

ASCO 2023: Dr. Jennifer Woyach on Combination Ibrutinib, Venetoclax, and Obinutuzumab for Previously Untreated CLL

Treatment Outcomes for Patients with CLL and SLL Treated with First Line Ibrutinib Versus Chemoimmunotherapy

A Study of Frontline Therapy in Adults 80 Years and Older with Chronic Lymphocytic Leukemia (CLL)

ASH 2022: Adverse Events from BTK Inhibitors in Clinical Trials

ASH 2022: Dr. Bill Wierda on Ibrutinib Combined with Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia (CLL)

ASH 2022: Dr. Neil Kay on Combination Therapies for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

ASH 2022: Dr. Bill Wierda on Acalabrutinib as a First-line Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT